Key Takeaways
- • South Korea's Financial Supervisory Service (FSS) and Korea Exchange (KRX) have implemented significantly tighter IPO screening standards, resulting in only nine new listings in Q1 2026—the lowest in five years—compared to 24 companies in Q1 2025.
- • The FSS is now requiring companies to provide more concrete earnings forecast justification in securities registration statements to prevent "inflated offering price" controversies, with Kanaph Therapeutics as a notable example of delayed listing due to correction requests.
- • Retail investor participation in IPO subscriptions has collapsed 76% year-over-year (four companies in early 2026 versus 17 in the same period of 2025), signaling suppressed market activity despite strong underlying stock market demand.
- • Regulatory reforms include introduction of priority allocation systems for lockup commitments, restrictions on small private equity manager and investment adviser participation in book-building, and adoption of cornerstone investor frameworks.
- • Financial authorities have signaled a "many births, many deaths" growth-first reform structure designed to lower listing barriers for high-growth companies while delisting insolvent firms, with IPO market momentum expected to recover once new systems are implemented.
Summary
South Korea's regulatory authorities have substantially tightened initial public offering standards following the so-called "FADU incident," which sparked controversy over inflated listing valuations. The Financial Supervisory Service and Korea Exchange have implemented stricter review protocols that have effectively chilled IPO activity despite robust underlying market conditions. In the first quarter of 2026, only nine companies achieved new listings on the Korea Exchange—one on the main board (Kbank) and eight on KOSDAQ—marking the lowest first-quarter performance in five years and representing a dramatic 63% decline from 24 listings in Q1 2025.
The FSS has intensified its scrutiny of securities registration statements, now demanding that companies provide substantially more rigorous and concrete justifications for earnings forecasts. This regulatory posture directly targets the root cause of past valuation controversies. Biotech firm Kanaph Therapeutics exemplifies the impact: after submitting its registration statement in early January 2026 with plans to conduct retail subscriptions by month-end, the company postponed its offering timeline following multiple correction requests from the FSS regarding its earnings projections.
Retail investor participation has contracted sharply, with only four companies conducting public offering subscriptions through mid-February 2026 compared to 17 companies during the same period in 2025—a 76% year-over-year decline. The regulatory tightening has also restricted participation in book-building by smaller private equity managers and investment advisers, while authorities have introduced priority allocation systems for lockup commitments and cornerstone investor frameworks to strengthen IPO integrity.
Despite the current market chill, financial authorities have signaled a strategic pivot toward what they term a "many births, many deaths" framework. This approach intends to lower entry barriers for high-growth companies while simultaneously facilitating delisting of insolvent enterprises. Once related system overhauls are completed, market participants expect IPO momentum to recover. Industry analysts note that some forecasts suggest 2026 total listings could reach only half the prior year's volume despite the buoyant broader equity market, underscoring the structural impact of regulatory reforms on capital formation.
The FSS has intensified its scrutiny of securities registration statements, now demanding that companies provide substantially more rigorous and concrete justifications for earnings forecasts. This regulatory posture directly targets the root cause of past valuation controversies. Biotech firm Kanaph Therapeutics exemplifies the impact: after submitting its registration statement in early January 2026 with plans to conduct retail subscriptions by month-end, the company postponed its offering timeline following multiple correction requests from the FSS regarding its earnings projections.
Retail investor participation has contracted sharply, with only four companies conducting public offering subscriptions through mid-February 2026 compared to 17 companies during the same period in 2025—a 76% year-over-year decline. The regulatory tightening has also restricted participation in book-building by smaller private equity managers and investment advisers, while authorities have introduced priority allocation systems for lockup commitments and cornerstone investor frameworks to strengthen IPO integrity.
Despite the current market chill, financial authorities have signaled a strategic pivot toward what they term a "many births, many deaths" framework. This approach intends to lower entry barriers for high-growth companies while simultaneously facilitating delisting of insolvent enterprises. Once related system overhauls are completed, market participants expect IPO momentum to recover. Industry analysts note that some forecasts suggest 2026 total listings could reach only half the prior year's volume despite the buoyant broader equity market, underscoring the structural impact of regulatory reforms on capital formation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.